JP2014506233A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506233A5
JP2014506233A5 JP2013538290A JP2013538290A JP2014506233A5 JP 2014506233 A5 JP2014506233 A5 JP 2014506233A5 JP 2013538290 A JP2013538290 A JP 2013538290A JP 2013538290 A JP2013538290 A JP 2013538290A JP 2014506233 A5 JP2014506233 A5 JP 2014506233A5
Authority
JP
Japan
Prior art keywords
emodin
digoxin
medicament
agent
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538290A
Other languages
English (en)
Other versions
JP5961622B2 (ja
JP2014506233A (ja
Filing date
Publication date
Priority claimed from US13/018,435 external-priority patent/US8541382B2/en
Application filed filed Critical
Publication of JP2014506233A publication Critical patent/JP2014506233A/ja
Publication of JP2014506233A5 publication Critical patent/JP2014506233A5/ja
Application granted granted Critical
Publication of JP5961622B2 publication Critical patent/JP5961622B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. 白血病、メラノーマ、結腸癌、前立腺癌、又は乳癌を治療するために構成された薬剤であって、約５ｕｇ／ｍｌ以上のエモジンと組み合わせた有効な量のジゴキシンを含む、薬剤。
  2. 約１０ｕｇ／ｍｌ以上のエモジンを含む、請求項１の薬剤。
  3. 約０．０５ｕｇ／ｍｌ以上のジゴキシンを含む、請求項１又は２の薬剤。
  4. 約０．１ｕｇ／ｍｌ以上のジゴキシンを含む、請求項１又は２の薬剤。
  5. 約１０ｕｇ／ｍｌ以上のエモジン及び約０．０５ｕｇ／ｍｌ以上のジゴキシンを含む、請求項１の薬剤。
  6. 約１０ｕｇ／ｍｌ以上のエモジン及び約０．１０ｕｇ／ｍｌ以上のジゴキシンを含む、請求項１の薬剤。
  7. 約５ｕｇ／ｍｌから約１０ｕｇ／ｍｌのエモジン及び約０．０５ｕｇ／ｍｌから約０．１ｕｇ／ｍｌのジゴキシンを含む、請求項１の薬剤。
  8. ＤＭＳＯを含む、請求項１〜７いずれか一項の薬剤。
  9. 前記エモジンがダイオウ（Rhubarb）、クロウメモドキ（Buckthorn）、及び／又はイタドリ（Japanese Knotweed）から抽出されたものである、請求項１〜８いずれか一項の薬剤。
  10. 前記エモジンがダイオウ（Rhubarb）の根茎から抽出されたものである、請求項１〜９いずれか一項の薬剤。
  11. 白血病、メラノーマ、結腸癌、前立腺癌、又は乳癌を治療するためのレジメン用に構成された薬剤であって、前記レジメンは約５ｕｇ／ｍｌ以上のエモジンと組み合わせた有効な量のジゴキシンを投与すること含む、薬剤。
  12. 約１０ｕｇ／ｍｌ以上のエモジンを含む、請求項１１の薬剤。
  13. 約０．０５ｕｇ／ｍｌ以上のジゴキシンを含む、請求項１１又は１２の薬剤。
  14. 約０．１ｕｇ／ｍｌ以上のジゴキシンを含む、請求項１１又は１２の薬剤。
  15. 約１０ｕｇ／ｍｌ以上のエモジン及び約０．０５ｕｇ／ｍｌ以上のジゴキシンを含む、請求項１１の薬剤。
JP2013538290A 2010-11-13 2011-11-13 癌治療のための、エモジンと併用する強心配糖体アナログ Expired - Fee Related JP5961622B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41343010P 2010-11-13 2010-11-13
US61/413,430 2010-11-13
US13/018,435 US8541382B2 (en) 2010-11-13 2011-02-01 Cardiac glycoside analogs in combination with emodin for cancer therapy
US13/018,435 2011-02-01
PCT/IB2011/003078 WO2012063134A2 (en) 2010-11-13 2011-11-13 Cardiac glycoside analogs in combination with emodin for cancer therapy

Publications (3)

Publication Number Publication Date
JP2014506233A JP2014506233A (ja) 2014-03-13
JP2014506233A5 true JP2014506233A5 (ja) 2015-01-08
JP5961622B2 JP5961622B2 (ja) 2016-08-02

Family

ID=46048345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538290A Expired - Fee Related JP5961622B2 (ja) 2010-11-13 2011-11-13 癌治療のための、エモジンと併用する強心配糖体アナログ

Country Status (4)

Country Link
US (2) US8541382B2 (ja)
EP (1) EP2637671A4 (ja)
JP (1) JP5961622B2 (ja)
WO (1) WO2012063134A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US8541382B2 (en) * 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US20170049687A1 (en) 2015-07-29 2017-02-23 Sirbal Ltd. Herbal Combinations For Treating Scalp Conditions
US9561245B2 (en) 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
US20140080772A1 (en) * 2012-09-06 2014-03-20 The Board Of Regents Of The University Of Texas System Treatments for melanoma
US9572828B2 (en) * 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
CN108697750A (zh) * 2015-10-01 2018-10-23 光动力公司 新型虎杖提取物及它们作为光动力灭活剂的用途
US9795570B2 (en) * 2016-03-17 2017-10-24 University Of South Carolina Modulation of macrophage phenotype by emodin

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2068027A (en) * 1935-05-09 1937-01-19 Rare Chemicals Inc Process of making glucosides from digitalis purpurea
US5872103A (en) 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
JPH06321795A (ja) 1993-05-07 1994-11-22 Kuga Takaaki アトピー性皮膚炎等の皮膚疾患治療薬
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
WO1997027848A1 (en) * 1996-01-31 1997-08-07 Board Of Regents, The University Of Texas System SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS
KR100221762B1 (ko) 1996-10-29 1999-09-15 이승기 에모딘의 항암제로서의 용도
SG60053A1 (en) 1997-04-10 1999-02-22 Chang Teh Shan Herb composition and an herbal plaster made from the same
TR200100560T2 (tr) 1998-08-18 2002-05-21 The Regents Of The University Of California EGF-R Antagonistlerinin uygulanmasıyla nefes yolunda mukus üretiminin önlenmesi
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US7534455B2 (en) 2000-03-09 2009-05-19 Yale University Herbal composition PHY906 and its use in chemotherapy
CN100490845C (zh) 2000-03-09 2009-05-27 耶鲁大学 一种草药组合物及其在化疗中的应用
IT1318547B1 (it) 2000-05-31 2003-08-27 Giorgio Palu Impiego dell'aloe-emodin nel trattamento di patologie neoplastiche diorigine neuroectodermica.
CN1369276A (zh) * 2001-02-12 2002-09-18 徐秀荣 有效减轻体重的组合物和方法
US20030125265A1 (en) * 2001-05-09 2003-07-03 Mien-Chie Hung Anti-estrogen receptor agents for chemotherapy
ITMI20010957A1 (it) 2001-05-10 2002-11-10 Giorgio Palu Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
WO2003067210A2 (en) 2001-07-10 2003-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of the multiple proteins in single cells
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CN1370587A (zh) 2002-03-05 2002-09-25 王舒妍 芦荟凝胶的制备方法
AU2003296335A1 (en) 2002-12-06 2004-06-30 Board Of Regents, The University Of Texas System Compositions and methods related to lipid:emodin formulations
US20050026849A1 (en) 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20050287667A1 (en) 2004-06-01 2005-12-29 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US20060205679A1 (en) 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
CN1796400B (zh) 2004-12-29 2010-06-23 杭州浙大力夫生物科技有限公司 从竹笋中提取的植物甾醇类提取物及其制备方法和用途
AU2006256374A1 (en) 2005-06-08 2006-12-14 Compugen Ltd. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US20070191262A1 (en) 2005-11-15 2007-08-16 University Of Iowa Research Foundation Cancer Therapy and Prevention Based on Modulation of Complement activity
CA2682385A1 (en) 2006-05-09 2007-11-15 Jr. Roland Valdes Treating cancer with cardiac glycosides
US20090018088A1 (en) 2006-10-27 2009-01-15 University Of Louisville Research Foundation Treating cancer with cardiac glycosides
AU2006350507A1 (en) 2006-11-09 2008-05-15 Unibioscreen S.A. Targeting of alpha-1 or alpha-3 subunit of Na+, K+-ATPase in the treatment of proliferative diseases
WO2008098789A2 (en) 2007-02-16 2008-08-21 Ktb Tumorforschungsgesellschaft Mbh Dual acting prodrugs
WO2008156654A2 (en) 2007-06-15 2008-12-24 Massachusetts Institute Of Technology Cytoskeleton modulators for treating metabolic disorders
EP2231165B1 (en) 2007-11-13 2013-05-15 Phoenix Biotechnology Inc. Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside
US20090269772A1 (en) 2008-04-29 2009-10-29 Andrea Califano Systems and methods for identifying combinations of compounds of therapeutic interest
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
CN101362702B (zh) 2008-09-12 2012-06-20 南昌大学 大黄素衍生物及其在制备抗癌药物中的应用
CA2739029C (en) 2008-10-14 2018-07-10 Nerium Biotechnology, Inc. Process for extracting cardiac glycosides from plants and compositions comprising cardiac glycosides from nerium oleander
US8541382B2 (en) 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US8597695B1 (en) * 2010-11-13 2013-12-03 Sirbal Ltd. Herbal combinations for treatment of a skin condition

Similar Documents

Publication Publication Date Title
JP2014506233A5 (ja)
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
WO2016004048A3 (en) Targeted conjugates and particles and formulations thereof
MX2015008503A (es) Conjugados dirigidos encapsulados en particulas y sus formulaciones.
JP2015500225A5 (ja)
EA033456B1 (ru) Конъюгаты антитело-лекарственное средство, содержащие пептидомиметические линкеры
JP2011079858A5 (ja)
JP2011522515A5 (ja)
CL2013003497A1 (es) Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.
GT200900128A (es) Antagonistas del receptor de progesterona
JP2016517888A5 (ja)
JP2015528491A5 (ja)
AR093382A1 (es) Dispositivo de administracion de farmacos para el tratamiento de pacientes con enfermedades respiratorias
TR201109804A2 (tr) Tek dozlu inhalasyon cihazı.
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
JP2013541583A5 (ja)
JP2015507020A5 (ja)
JP2014504636A5 (ja)
WO2016040462A3 (en) Formulations and methods for treatment of metabolic syndrome
JP2013100286A5 (ja)
WO2017013490A3 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
JP2015500286A5 (ja)
JP2015529664A5 (ja)
EA201590732A1 (ru) Диспергируемая таблетка
JP2010519274A5 (ja)